U.S. Markets open in 6 hrs 7 mins

Unigene Laboratories Inc. (UGNEQ)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00040.0000 (0.0000%)
At close: 12:12PM EDT
People also watch

Unigene Laboratories Inc.

81 Fulton Street
Boonton, NJ 07005
United States

Full Time Employees53

Key Executives

Mr. Ashleigh W. PalmerChief Exec. Officer, Pres and Director427.19kN/A54
Mr. Brian Zietsman CPAChief Financial Officer and Principal Accounting Officer169.89kN/A53
Dr. Nozer M. Mehta Ph.D.Chief Scientific Officer267.62kN/A69
Dr. J. Thomas August M.D.Director of ResearchN/AN/A89
Ms. Roxanne TavakkolVP of Global Regulatory Affairs & Quality AssuranceN/AN/A54
Amounts are as of December 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and drug delivery of peptides for therapeutic use in the United States. Its patented oral and nasal drug delivery technologies deliver therapeutically useful amounts of various peptides into the bloodstream. The company offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. It is also developing oral calcitonin that has completed a Phase III testing for the treatment of osteoporosis. In addition, the company is also developing a pre-clinical anorexigenic peptide, UGP281 for obesity. It has license agreements with Tarsa Therapeutics, Inc. and Novartis Pharma AG for the development of oral calcitonin program. Unigene Laboratories, Inc. was founded in 1980 and is headquartered in Boonton, New Jersey. On July 2, 2013, Unigene Laboratories Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of New Jersey.

Corporate Governance

Unigene Laboratories Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.